Dermatology Case Answer C: May

Back to the question.

Dr. Femia is a fellow in the dermatology–rheumatology fellowship at Brigham and Women’s Hospital in Boston. She is a diplomat of the American Board of Dermatology.

Dr. Merola is an instructor in the department of dermatology at Harvard Medical School and a fellow in the rheumatology division at Brigham and Women’s Hospital, both in Boston. He is the assistant program director for the combined medicine–dermatology training program and a diplomat of the American Board of Dermatology and the American Board of Internal Medicine.

References

1. Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumor necrosis factor alpha therapy and increased risk of de novo psoriasis: Is it really a paradoxical side effect? Clin Exp Rheumatol. 2012 Aug. [Epub ahead of print]
2. Wollina U, Hansel G, Koch A, Schoonlebe J, Kosteler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1-14.
3. Perman MJ, Lovell DJ, Denson LA, Farrell MK, Lucky AW. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol. 2012;29:454-459.
4. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318-1327.
5. Denadai R, Teixeira FV, Steinwurz F, Romitis R, Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: A systematic literature review based on 222 cases. J Crohns Colitis. 2012 Sep 6. [Epub ahead of print]
6. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-240.
7. Cohen JD, Bournerias I, Buffard V, et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: A case series. J Rheumatol. 2007;34:380-385.
8. Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol. 2010;163:1116-1118.
9. Chu D, Van Voorhees A, Rosenbach M. Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: A report of two cases. Arch Dermatol. 2011;147:1228-1229.